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Abstract
Lymph node metastasis indicates poor prognosis in esophageal cancer. To understand the underlying mechanisms, most
studies so far focused on investigating the tumors themselves and/or invaded lymph nodes. However they neglected the
potential events within the metastatic niche, which precede invasion. Here we report the first description of these
regulations in patients on transcription level. We determined transcriptomic profiles of still metastasis-free regional lymph
nodes for two patient groups: patients classified as pN1 (n = 9, metastatic nodes exist) or pN0 (n = 5, no metastatic nodes
exist). All investigated lymph nodes, also those from pN1 patients, were still metastasis-free. The results show that regional
lymph nodes of pN1 patients differ decisively from those of pN0 patients – even before metastasis has taken place. In the
pN0 group distinct immune response patterns were observed. In contrast, lymph nodes of the pN1 group exhibited a clear
profile of reduced immune response and reduced proliferation, but increased apoptosis, enhanced hypoplasia and
morphological conversion processes. DKK1 was the most significant gene associated with the molecular mechanisms taking
place in lymph nodes of patients suffering from metastasis (pN1). We assume that the two molecular profiles observed
constitute different stages of a progressive disease. Finally we suggest that DKK1 might play an important role within the
mechanisms leading to lymph node metastasis.
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Introduction
In esophageal cancer (ESC), lymph node metastasis is associated
with poor prognosis. During the migration of tumor cells through
lymph vessels and during their homing in lymph nodes, these
tumor cells get into close contact to endothelial cells and lymph
node sinus. Tumor expansion currently forms the main basis for
therapy selection. But despite the high prognostic relevance of
lymphogenic metastases, the molecular mechanisms underlying
this metastatic pathway are still mostly unknown.
A number of studies investigated the molecular profiles of the
tumors[1–4] and/or the metastatic lymph nodes.[5] Further
studies investigated lymphogenic metastasis in correlation with
lymphatic angiogenesis[6–9] and chemokine associated[10–12]
migration. It was assumed that directed migration of esophageal
carcinoma cells might be guided by locally expressed chemo-
kines.[12] And based on these findings it would be imaginable that
the homing process into the lymph nodes might be assisted by
lectin-glycan-interactions between the tumor cells and lymph
endothelial cells. Hirakawa et al.[13] demonstrated that in mice
even before metastasizing, primary tumors (skin cancer) might
stimulate sentinel lymph node lymphangiogenesis. They suggested
that primary tumors could be capable of preparing their future
metastatic niche by producing lymphangiogenic factors that might
mediate their efficient transport to the sentinel lymph nodes.
Yet, to the authors’ best knowledge there is no published work
specifically examining the early molecular mechanisms in this
metastatic niche in patients – mechanisms within the non-affected
lymph nodes, which could propagate or suppress early metastasis
in patients suffering from ESC.
The aim of this study therefore was to specifically investigate
these early alterations in lymph nodes prior to histopathologically
detectable metastasis. The work has been driven by the hypothesis
that before tumor cells metastasize to regional lymph nodes,
important changes must have already taken place propagating or
suppressing the homing process. To get insight into this process,
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we collected tumor regional and distant lymph nodes from patients
suffering from ESC staged as pN0 (no metastatic nodes exist) or
pN1 (metastatic nodes exist). All lymph nodes included in the
analysis were metastasis-free – irrespective of the patient staging.
We performed microarray analyses and investigated the mecha-
nisms linked to the genes differentially expressed between regional
and distant lymph nodes of the same patient.
Key to our work here are two features. First, all analyzed lymph
nodes without exception, even those of the pN1 patients, were still
free of metastasis. Second, we used samples of patients who did not
undergo any neoadjuvant radio-chemotherapy and established
further procedures that ensured very high sample quality.
Materials and Methods
General analysis workflow
The included patients suffered from esophageal cancer and
underwent a radical thoraco-abdominal en-bloc esophagectomy
including lymph node dissection of the upper and lower
mediastinum (R0 resection) without neoadjuvant radio-chemo-
therapy. We included only lymph nodes from patients staged as
pN0 (regional lymph nodes free of metastasis) or pN1 (regional
lymph nodes metastasis present) and verified by histopathology
that the lymph nodes selected for our analysis were all tumor cell
free. We also confirmed by immunohistology that these lymph
nodes were free of micro-metastasis. We isolated from each lymph
node total RNA for microarray expression analysis. A paired T-
test was used for the identification of genes that were differentially
expressed between regional and distant lymph nodes and a
functional enrichment and network analysis was performed.
Subsequently major candidates were validated via real time
PCR and DKK1 was validated in addition via immunohistological
staining.
Experiment design
The aim of the work presented here was to identify potential
factors facilitating and driving metastasis in lymph nodes of
patients suffering from esophageal carcinoma. To enable such
understanding the experiment design (Fig. 1) incorporated two
variables of interest.
First, samples were classified according to the principal status of
the patients exhibiting (pN1 group) or non-exhibiting (pN0 group)
metastasis in regional lymph nodes. The comparison of pN1 and
pN0 patients should highlight the general differences in regulations
that might lead to or prevent from metastasis.
Second, two lymph node samples were collected from each
patient, one node located close to the tumor (regional) and the
second node distant to the tumor. While the distant nodes served
as reference sample the regional nodes were investigated for
transcriptional regulations. The pairwise comparison of the tumor
distant samples with the patient specific regional nodes should
reveal the early regulations potentially resulting from the location
close to the tumor. In this publication the term ‘‘up-regulation’’ is
used for those genes and functions that exhibit a higher expression
in the regional lymph nodes in comparison to the distant lymph
nodes. Conversely, those genes and functions that are decreased in
the regional lymph nodes are termed ‘‘down-regulated’’.
It is important to note that all nodes investigated were made
sure to be still metastasis free, independent of the patients’ pN1/
pN0 classification and of the location relative to the tumor. This
should allow the identification of early changes occurring prior to
metastasis homing.
Ethics committee approval & patients consent
This study was performed in accordance with the applicable
regulations and was approved by the Hamburg Ethics Committee,
Germany, under vote number PV3548. Patients written consent to
participate in the study was collected in accordance with the
applicable regulations.
Sample material
Overall samples from 22 patients with esophagus carcinoma
were analyzed of which 14 sample pairs exhibited an adequate
sample quality. For each patient sample pairs of tumor close and
tumor distant lymph nodes were collected to reduce inter-
individual differences that might occur due to diverging genetic
background. Lymph nodes were immediately dissected upon
extraction in the operation room. The segments that were
dedicated for the microarray expression analysis were directly
transported in liquid nitrogen to the laboratory for RNA
extraction. The other part of the lymph nodes was embedded in
paraffin for classification and diagnosis.
Operation procedure
After histological diagnosis of an esophageal carcinoma, patients
with early stage lesions (pT1a) were referred to surgery either if the
endoscopic resection was incomplete or the tumor was staged as
pT1b. Patients were directly referred to surgery if the preoperative
staging was suspicious for either muscular wall involvement (cT2)
or lymph node involvement (cN1). No patient was submitted to
neoadjuvant therapy.
All patients underwent median T-shaped laparatomy and right-
sided thoracotomy. For patients with collar anastomosis an
additional left-sided cervicotomy for collar anastomosis was
performed. Every patient received a radical en bloc esophagec-
tomy with resection of the esophagus, thoracic duct, azygos vein,
ipsilateral pleura, and all periesophageal tissue in the posterior
mediastinum. Reconstruction was performed by gastric tube or
colon interposition usually with a high intrathoracic or cervical
anastomosis.
Additionally, a standardized two-field lymphadenectomy was
performed. All lymph nodes were systematically sampled from
eight locations: regional mediastinal, both in the vicinity of the
tumor and distant from it; infraclavicular; diaphragmatic (lower
mediastinal); perigastric lymph nodes (including left and right
pericardial); common hepatic artery lymph nodes; and lymph
nodes at the celiac trunk. All nodes were mapped by the surgeon
according to the scheme of the American Thoracic Society as
modified by Casson et al.[14] All resected specimens were assessed
by a senior pathologist.
Postoperative follow-up was carried out as part of the usual
aftercare. Patients were seen at the outpatient clinic at 3- to 4-
month intervals for the first 2 years and at 6-month intervals
thereafter. Follow-up evaluation included physical examination,
plain chest radiography, abdominal ultrasonography, endoscopy,
endosonography, CT of the chest and abdomen, with PET-CT
after January 2006 in selected cases, CEA and CA 19-9 tumor
marker studies, and bone scans. Whenever relapse was suspected,
additional radiologic, endoscopic, or histologic confirmation was
sought.
Recurrence was diagnosed if proven by biopsy or by unequiv-
ocal evidence of tumor masses (newly appearing metastases or
local recurrence) with a tendency to grow during further follow-up
and/or follow-up until death. Recurrent disease was defined as
either locoregional (occurring in the upper abdomen or medias-
tium) or as distant metastasis.
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Micrometastasis staining
Hematoxylin and eosin staining was used for tumor cell
detection in a first diagnostic step. Histologically ‘‘tumor-free’’
lymph nodes were then screened immunohistochemically using
anti–cytokeratin antibody AE1/AE3 (Dako, Glostrup, Denmark)
diluted 1:50 (v/v) by the biotin-streptavidin method as described
previously.[15] AE1/AE3 is a cocktail of two antibodies that
recognizes basic and acidic CK’s on the surface and in the
cytoplasm of all epithelial cells (except parietal cells, hepatocytes,
and the superficial layers of squamous epithelium). The antibodies
do not react with mesenchymal tissue, including lymphoid
tissue[16].
Formalin fixed and paraffin embedded sections of 5 to 6 mm
thickness were cut at three different levels in each node and
deparaffinized according to standard histological techniques and
transferred onto glass slides treated with 3-triethoxysilylpropyla-
min (Merck, Darmstadt, Germany). One section of the sample
obtained at each level was stained using alkaline phosphatase–anti-
alkaline phosphatase technique combined with the new fuchsine
stain (Sena, Heidelberg, Germany) for the visualization reac-
tion[17].
Sections of normal colon mucosa served as positive staining
controls and isotype-matched, irrelevant murine monoclonal
antibodies served as negative controls (purified immunoglobulin
mouse myeloma protein for IgG1; Sigma, Deisenhofen, Ger-
many).
The slides were evaluated in a blinded procedure by two
independent investigators. In case of incongruent findings a third
investigator was consulted and a consensual decision was made.
Minimal tumor cell involvement in a lymph node that was
considered to be tumor-free by conventional histological staining
was defined as the presence of one to ten positive cells in the body
of the node.
Sample preparation and purification
Isolation of total RNA from liquid nitrogen frozen lymph node
samples was performed with the Trizol from Invitrogen according
to the manufacturers protocol (Rev. date 12. June 2007) and was
purified afterwards with the Qiagen RNeasy-Mini-Kit. Concen-
trations were determined with a PeqLab NanoDrop photometer
and RNA quality by capillary electrophoresis using an Agilent
Bioanalyzer 2100 System. Out of the 22 sample pairs 9 pairs of
patients with observed far metastasis and 5 sample pairs of patients
with no far metastasis observed showed an RNA quality sufficient
for the following analysis.
Microarray analysis
Microarray experiments were performed using Affymetrix
human whole genome GeneChips U133 Plus 2.0 (Affymetrix,
Figure 1. Experimental design. Lymph nodes of two different patient groups suffering (pN1) or not suffering (pN0) from lymph node metastasis
were investigated. From each patient regional lymph nodes (adjacent to the tumor) were compared to distant lymph nodes (reference as baseline).
Key to the experiment is that all investigated lymph nodes, including those of pN1 patients, were made sure to be still free of metastasis as well as
micro-metastases.
doi:10.1371/journal.pone.0102552.g001
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Santa Clara, USA) according the manufacturers protocol. To
prepare the RNA for the expression arrays cDNA-synthesis with
preceding photometric determination of the RNA concentration
was performed. The following steps were performed using 250ng
of total RNA for the first strand synthesis. Sample preparation
incorporated steps for cDNA synthesis, purification, synthesis of
the biotin-labled cRNA, in vitro transcription, fragmentation,
hybridization as well as washing and staining. The preparation
was performed according to the One Cycle Protocol using the
GeneChip 3’ IVT Express Kit from Affymetrix. For Hybridization
12.5 mg fragmented cRNA were used. The arrays were incubated
for 16h in the Affymetrix Hybidization Oven 640 at 45uC.
Washing and staining steps were performed semi-automatic in the
Affymetrix Fluidics Station 450, the single steps following the
Affymetrix One Cycle Protocol for standard arrays. After washing
and staining the arrays were scanned using the Affymetrix
GeneChip Scanner 3000 7G and the Command Console software
at a wavelength of 570 nm and a pixel size of 1.56 mm.
Statistical analysis
Lymph nodes from both patient groups (pN0 and pN1) were
analyzed independently. As the focus of this work were early
changes preceding metastasis, only metastasis free lymph nodes
were analyzed. The tumor distant lymph node samples were used
as reference for the paired regional lymph nodes.
Background correction and normalization were performed
using RMA procedure and quantile normalization. A paired T-
test within the two groups (pN0, pN1) was performed and a
bootstrapping procedure was performed to adjust for false positive
regulations. As cutoff values a corrected p-value of 0.05, a raw p-
value of 0.01 and a signal-log-ratio (SLR) of 60.7 were used to
determine the top regulated genes.
Following differential gene expression analysis we performed
gene set enrichment and network analysis with Ingenuity Pathway
Analysis software (Ingenuity Systems, version 162830). For the
analysis the corrected p-value cutoff was set to a less stringent
value of 60.1 to allow for the incorporation of more subtle
changes.
Validation via RT-PCR
Twelve of the determined candidate genes were validated via
RT-PCR using three technical replicates per sample. The RT-
PCR was performed with 96-well plates on the StepOne Plus real
Time PCR System from Applied Biosystems. For each sample 2 ml
with a concentration of 5 ng/ml were used. To account for
fluctuations in sample concentration Beta-2-microglobulin (B2M)
was taken as housekeeping reference. For determination of the
regulations on expression level the mean value of the three
technical replicates’ delta-Ct-values was calculated. Significance of
the changes was determined using a paired t-test between tumor
close and tumor distant mean delta-Ct-values within each group
(pN0, pN1).
DKK1 Immunohistochemistry
Immunohistochemistry was performed on paraffin sections of
the investigated lymph nodes using polyclonal antibody against
DKK1 (1:100, abcam, #ab61034). For immunohistochemical
detection sections were deparaffinized, rehydrated, and pre-
treated with 0.1% pronase, for 10 min for enzymatic antigen
unmasking. After incubation in 3% hydrogen peroxide for 15 min
to block endogenous peroxidase activity and incubation with 5%
BSA for 30 min to block non-specific antibody binding primary
antibody was applied. Immunohistochemical staining was per-
formed over night at 4uC. A biotinylated secondary goat anti-
rabbit IgG (1:200, Dako Cytomation) was used, followed by
incubation with a streptavidin/HRP (1:200, Dako Cytomation) as
a third antibody. Peroxidase activity was detected using DAB as
chromogenic substrate (Dako Cytomation). Sections were coun-
terstained with hematoxylin, dehydrated, and mounted. Images
were collected on a Zeiss Mirax MIDI slide scanner (Zeiss) and
images were captured using the Pannoramic Viewer software.
Results
Metastasis-free regional lymph nodes differ between pN1
and pN0 patients on transcriptomic level
We asked if a) the metastatic niche in lymph nodes might be
affected even before metastasis has taken place and if b) still
metastasis-free lymph nodes of pN1 patients might be more on the
verge of metastatic invasion than those of pN0 patients and if c)
therefore those ‘‘pN1’’ lymph nodes might exhibit distinct
transcriptional deregulations associated with the niche prepara-
tion.
We included tumor regional lymph nodes from 14 esophageal
carcinoma patients (n = 9 pN1 patients; n = 5 pN0 patients) to
investigate gene expression in the potential metastatic niche. In
addition we collected a paired tumor distant lymph node from
each patient to serve as reference for the regional nodes (Fig. 1).
Afterwards they were analyzed on transcriptomic level by
microarray technology.
Key to the work presented here is that all nodes investigated
were confirmed to be histopathologically and immunohistologi-
cally metastasis and micrometastasis-free, independent of patients’
pN1/pN0 classification and of the location relative to the tumor.
This should allow identification of early changes occurring prior to
metastasis homing. Information about patients’ age, gender,
histology or classifications is provided in Table S1.
To identify the potential pre-invasive changes we compared the
regional lymph nodes with the distant lymph nodes using a paired
T-test within the two groups (pN0, pN1). The tumor distant lymph
nodes served as reference for the regional nodes, such that up-
regulations depict those genes with a higher expression level in the
regional nodes and down-regulations respectively those genes with
a lower expression level. The T-test was followed by a boot-
strapping procedure to account for multiple testing. As cutoff
values a corrected p-value of 0.05, a raw p-value of 0.01 and a
signal-log-ratio (SLR) of 60.7 were used to determine the top
regulated genes. The most significant candidates identified are
displayed in Table 1, complete statistics are provided in Table S2.
Applying these thresholds we identified 173 transcripts (128
genes) significantly regulated between regional and distant lymph
nodes of pN0-classified patients. Several of these genes were
associated with immune response (such as CD64, CD32, FPR1
and FPR2,[18] IGHG1, IL1R2, CCL23, MSR1, C5AR1,
LILRA5,[19] or LILRB2[20]). Interestingly a couple of cancer
and metastasis associated genes were deregulated as well (such as
L1CAM (CD171),[21] EREG,[22,23] NOVA1, HPR,[24] or
LAMC2[25,26]). Epiregulin, e.g., is an angiogenic factor that
can propagate metastasis by enabling tumor cells to breach lung
endothelial barriers and in turn by releasing them into the
circulation system[22,23].
In contrast we identified 134 dysregulated transcripts (109 genes
including IGF1, DKK1, PRIMA1 and LTF) in the regional lymph
nodes of pN1-classified patients. Among those genes pro-prolifer-
ative and anti-apoptotic molecules were down-regulated – such as
IGF1 and LTF which act through regulation of the AKT signaling
pathway[27] and ERK1/2 pathway[28] respectively. PRIMA1
modulates CXCR4 expression[29] – a molecule that already has
Premetastatic Niche in Human Esophageal Lymph Nodes
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been described to correlate strongly with increased lymphatic
metastasis[11,12,29].
Notably DKK1 exhibited the most significant deregulation (2-
fold change; p-value of 0.0029). The gene was clearly down-
regulated in the regional lymph nodes of pN1 patients. DKK1 is a
WNT pathway inhibitor that has been shown to be of prognostic
significance in diverse tumor entities such as breast cancer, lung
cancer, myeloma but also in esophageal carcinoma.[30–38] In
addition DKK1 was reported to be elevated in the serum of ESC
patients[37].
We validated 12 of the most significant genes via RT-PCR
(Fig. 2). For five of these genes (ISL1, LAMC2, NOVA1, EREG,
L1CAM) the regulation tendencies and strengths were confirmed
though the p-values determined in the PCR analysis ranged
between 0.08 and 0.15, probably due to the small sample size.
Seven genes (IGF1, IGFBP5, DKK1, LTF, TBX3, FOXG1,
LILRA) could be validated successfully showing a significant p-
value below of 0.05. Highest significance (p-value of 3*10e-4) was
observed again for DKK1 (see Table S3).
By the time of follow-up analysis five pN1 patients had died as
well as one pN0 patient. The latter patient had exhibited lung
metastasis in a follow-up examination. Interestingly this patient
constitutes an outlier in terms of DKK1 expression showing a
down-regulation in the regional lymph nodes.
The results described in this section show that these metastasis-
free pN1 lymph nodes exhibit gene regulations clearly different
Table 1. Top regulated genes in pN0 and pN1 patients’ regional lymph nodes.
Dysregulations in pN1 regional lymph nodes
Unique ID raw p-value pN1 corr. p-value pN1 SLR pN1 SYMBOL Entrez ID
204602_at 0.0029 0.000 21.0 DKK1 22943
202018_s_at 0.0095 0.014 21.0 LTF 4057
235944_at 0.0076 0.005 20.9 HMCN1 83872
202765_s_at 0.0090 0.006 20.9 FBN1 2200
219682_s_at 0.0023 0.001 20.8 TBX3 6926
227526_at 0.0043 0.007 20.8 CDON 50937
231807_at 0.0085 0.006 20.8 KIAA1217 56243
221024_s_at 0.0094 0.004 20.7 SLC2A10 81031
238029_s_at 0.0078 0.010 20.7 SLC16A14 151473
230087_at 0.0049 0.006 20.7 PRIMA1 145270
206018_at 0.0068 0.004 1.4 FOXG1 2290
Dysregulations in pN0 regional lymph nodes
Unique ID raw p-value pN0 corr. p-value pN0 SLR pN0 SYMBOL Entrez ID
202267_at 0.0058 0.000 20.9 LAMC2 3918
223805_at 0.0018 0.008 20.8 OSBPL6 114880
202341_s_at 0.0044 0.016 20.7 TRIM2 23321
237390_at 0.0041 0.000 20.7 NA NA
202342_s_at 0.0053 0.008 20.7 TRIM2 23321
205794_s_at 0.0058 0.000 20.7 NOVA1 4857
204584_at 0.0085 0.008 20.7 L1CAM 3897
227461_at 0.0042 0.000 20.7 STON2 85439
236926_at 0.0085 0.032 20.7 TBX1 6899
1552575_a_at 0.0068 0.024 20.7 C6orf141 135398
219867_at 0.0088 0.000 20.7 CHODL 140578
244655_at 0.0079 0.008 20.7 LOC100132798 100132798
226770_at 0.0030 0.015 20.7 MAGI3 260425
1553622_a_at 0.0065 0.000 20.7 FSIP1 161835
219316_s_at 0.0029 0.000 0.7 FLVCR2 55640
210845_s_at 0.0022 0.000 0.8 PLAUR 5329
211924_s_at 0.0066 0.000 0.8 PLAUR 5329
203561_at 0.0029 0.000 0.8 FCGR2A 2212
204429_s_at 0.0062 0.000 0.9 SLC2A5 6518
205767_at 0.0061 0.000 1.2 EREG 2069
220088_at 0.0014 0.000 1.4 C5AR1 728
1555643_s_at 0.0085 0.015 1.5 LILRA5 353514
The table includes the unique ids (Affymetrix Probeset), raw p-values, corrected p-values (bootstrapping), signal-log-ratios and gene description.
doi:10.1371/journal.pone.0102552.t001
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from those in pN0 lymph nodes. Furthermore they indicate that
DKK1 might be significantly associated with the underlying
mechanisms.
The functional patterns in pN0 and pN1 samples are
distinct but tightly connected
Based on these findings we asked whether the observed
regulations indeed depict different molecular mechanisms – or
merely different representatives of the same mechanisms. We
therefore performed gene set enrichment and network analysis.
Because sample size used in our work is rather small the p-value
distribution is affected in the T-test. Taking this into account and
to allow for incorporation of more subtle changes, which
nevertheless might add to the big picture, we decided to use a
less stringent p-value of 60.1 to identify regulated genes to be
included in the analysis.
Our analysis revealed strikingly distinct profiles (Fig. 3) char-
acterizing the tumor-adjacent lymph nodes of the pN1 and pN0
patients. The results showed a clear activation of immune response
mechanisms in the pN0 group. The regulated genes were
associated with enhanced inflammatory response, antigen presen-
tation, reduced cellular growth, immune cell tracking and cell-to-
cell signaling, while proliferation and cancer-associated mecha-
nisms were reduced.
In contrast regional lymph nodes of pN1 patients exhibited a
reduction of immune response associated mechanisms (Fig. 3). In
addition, reduced proliferation as well as reduced tissue structure,
morphology and development was observed on the one hand –
and enhanced apoptosis and hypoplasia on the other. Time wise it
should be expected that these lymph nodes would be closer to the
point of metastatic invasion so it was surprising that the immune
response pattern was down-regulated.
Furthermore the analysis predicted an inactivation of b-catenin
and downstream regulators (Fig. 4a). Among the major b-catenin
targets, VEGFA, CCND1, MSX1, IGFBP5 and DKK1 exhibited
a decreased expression on the microarray. Though only based on
statistical probabilities, the prediction is notable because active b-
catenin is required for DKK1 expression.[39] The potential
inactivity of b-catenin therefore might correlate with the observed
down-regulation of DKK1.
To further investigate how related the underlying molecular
pathways are, we included the gene expression regulations
observed in pN1 samples (109 genes) and in pN0 samples (128
genes) in one common list and performed network analysis.
Interestingly, despite the clear difference in molecular mechanism
profiles between pN1 and pN0 samples, the analysis revealed that
several of the involved genes (28/128 pN0 genes; 19/109 pN1
genes) seemed to be tightly connected (Fig. 4b) across both groups
– with DKK1 embedded within the network.
Taken together these observations suggest that metastasis-free
regional lymph nodes of pN1 patients are already subject to
molecular processes different to those of pN0 patients – though
metastasis has not yet taken place in these nodes. In addition an
involvement of DKK1 regulation via the WNT/b-catenin
pathway seems more plausible. This being said, the molecular
networks underlying these different patterns might be connected.
In ESC patients lymph node metastasis is only a question of time
unless a timely tumor resection is performed. Therefore it seems
plausible that the observed transcriptional patterns do not
correlate with two totally different mechanisms but rather depict
two time points of a progressing process.
DKK1 can be observed in distinct substructures of the
lymph node and in vessel endothelial cells
Because of the significance of DKK1 in our results and because
DKK1 has already been shown to be prognostic for the outcome
of a number of malignant tumor entities[30-38] we focused on this
molecule in immunohistochemical validation. We stained paraffin
sections of the investigated lymph nodes using a polyclonal
antibody against DKK1 and counterstained the sections with
hematoxylin. The immunohistochemical staining revealed a
tendency of DKK1 to be less expressed in regional pN1 patients’
lymph nodes (Fig. 5a). In DKK1 positive lymph nodes its
expression could be clearly observed in the subcapsular sinus
and in some cases extending into the intermediary sinus and
trabeculae (Fig. 5b). Furthermore in a couple of samples DKK1
expression could be observed in vessel endothelial cells (Fig. 5c).
Discussion
While several cancer incidence rates dropped in the United
states and other Western countries over the last decades the
incidence rate of esophageal adenocarcinoma has increased.[40]
Figure 2. RT-PCR results for validation of microarray results.
Displayed the signal-log-ratios of the regional lymph nodes in
comparison to the tumor distant lymph nodes (reference) for a selected
set of top regulated genes.
doi:10.1371/journal.pone.0102552.g002
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One parameters indicating disease progression is tumor expansion
that currently forms the basis for therapy selection. Still, the
molecular mechanisms of lymphogenic metastasis are mostly
unknown. Several studies investigated the molecular profiles of
esophageal cancer (ESC),[1-4] patient serum[37] and/or the
invaded lymph nodes.[5] But to the authors best knowledge only
few published studies investigated the pre-metastatic niche in
lymph nodes of other cancers[13,41,42] in mice and none has
investigated the metastatic niche for ESC prior to invasion in
patients.
Our scope was to investigate this pre-metastatic niche in
patients suffering from ESC and to determine the potential factors
involved in early metastatic spread of tumor cells to lymph nodes.
We hypothesized that the regional lymph nodes (adjacent to the
tumor) might be more prone to be invaded first than the far lymph
nodes. In consequence we used microarray technology to analyze
these regional lymph nodes of ESC patients whom either suffered
(pN1) or did not suffer (pN0) from lymphogenic metastasis at the
time point of surgical intervention.
As there is evidence that squamous cell carcinoma (SCC) and
adenocarcinoma (AC) of the esophagus might differ in their tumor
progression one could imagine that these differences might have
an impact on our observations. While SCCs are mainly observed
in the proximal esophagus and are ascribed to smoking or alcohol
abuse, ACs usually occur in the distal esophagus and are
frequently preceded by Barrett’s disease or gastroesophageal
reflux disease. There are hints, that the tumor type might affect
the location of lymph node metastasis.[43] However we assume
that this is attributable to tumor location, not to histotype-specific
molecular metastasis-pathways. In this study we assumed that both
tumor histotypes might share some common molecular mecha-
nisms within their metastatic cascade. To take this effect into
Figure 3. Functional gene set enrichment. Displayed are biological and molecular functions and sub-functions associated with the genes
regulated in regional lymph nodes in comparison to the distant lymph nodes (reference) of pN1 or pN0 patients. The single transparent circles depict
the main functions, the colored (red: activated, blue: inactivated) circles within depict the significantly enriched sub-functions (e.g. within pN1 cell
death circle: ‘apoptosis of leukemia cell lines’ – red, or ‘cell survival’ – blue). Blue sub-functions have a strong prediction to be inactivated, red sub-
functions to be activated. The deeper the color the more reliable (z-score) is the activation state’s prediction. The size of the circles increases with the
significance (p-value) of the gene list’s association with the sub-functions. The analysis was performed with Ingenuity Pathway Analysis software. It
can be clearly seen that metastasis-free regional lymph nodes of pN1 patients exhibit a completely different regulation-pattern that those of pN0
patients.
doi:10.1371/journal.pone.0102552.g003
Figure 4. Network analysis. The network analysis was performed using Ingenuity Pathway Analysis software. a) Mechanistic network of b-catenin
downstream regulators displaying predicted activation state and the regulatory relation (activation or inhibition) between the single regulators. b-
catenin and a number of downstream regulators are predicted to be inactivated. b) The analysis shows a tight connection between the genes
regulated in the pN1 samples (light grey nodes) and those regulated in the pN0 samples (dark grey nodes) linked by ERK1/2 and DKK1 embedded
within the network.
doi:10.1371/journal.pone.0102552.g004
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account and to prevent a bias we distributed squamous cell
carcinoma and adenocarcinoma over the analyzed groups (pN0
and pN1), see Table S1.
The sample size in our work (pN1 n= 9; pN0 n=5) is small and
the authors are aware that these numbers are below the power
necessary for solid prognostic studies. This sample size goes back
to the stringent quality selection process that the samples
underwent before being included in our study. Only patients that
did not undergo neoadjuvant radio-chemotherapy were included
in the study. The lymph node segments dedicated for expression
analysis were immediately dissected upon extraction in the
operating room and directly transported in liquid nitrogen to the
laboratory for RNA extraction. The other part of the lymph nodes
was embedded in paraffin for diagnosis. And finally and foremost
only metastasis- and micro-metastasis-free lymph nodes were
included in the study, even for pN1 patients. The power of the
work presented here is therefore the quality assurance process and
the novel experimental design (see Fig. 1).
The results of this study suggest that regional lymph nodes of
ESC patients might undergo alterations prior to metastatic
invasion. This assumption is derived from the observation that
lymph nodes of pN0 and pN1 patients exhibit clearly distinct
transcriptional patterns (Fig. 3). While the transcriptional regula-
tions in pN0 patients’ lymph nodes clearly indicate an enhanced
immune response those regulations observed in pN1 patients
indicate a reduced immune response, reduced proliferation,
reduced cancer associated mechanisms and enhanced apoptosis.
We assume that the enhanced immune response in the pN0
lymph nodes might result from a lymph node’s exposure to
circulating tumor cells or signaling processes of the primary tumor.
An effective immune response might prevent these lymph nodes
from metastatic invasion. The reduction of the immune response
pattern in the pN1 lymph nodes might indicate a loss of this
protective shield. This loss might provide circulating tumor cells an
enhanced chance of survival. The observed reduction of prolifer-
ation and cancer & tumor morphology patterns as well as the
enhanced apoptosis is primarily surprising and intriguing in terms
of carcinogenesis. However, it has to be considered that at this
point the investigated tissue constitutes the metastatic niche – not
the metastasis itself or invaded lymph nodes. Increased apoptosis
and reduced proliferation would suggest a morphological remod-
eling process in the lymph nodes that could facilitate invasion.
Approximately all ESC patients tend to develop metastasis if not
treated in time. Therefore, we assume that these two different
patterns do not reflect completely different molecular pathways
but rather two different stages of a progressing disease. We assume
that key molecules might mark the transition from one state to the
next and that DKK1 might be one of these molecules.
An up-regulation of DKK1 has already been described in the
context of diverse malignant tumors such as breast cancer, lung
cancer, myeloma or even esophageal cancer.[30-38] In these
studies DKK1 was investigated in context of the tumor itself or as
molecule potentially secreted by the tumor into patients’ serum. In
breast cancer DKK1 is assumed to prepare the metastatic niche in
the bone by deregulating the equilibrium between osteoclasts and
osteoblasts.[44] These mechanisms however cannot be transferred
to lymph nodes, especially because native DKK1 is down-
regulated here.
Notably our immunohistochemical staining (Fig. 5) showed that
before down-regulation, DKK1 could be observed not only within
the subcapsular sinus and in parts within the intermediary sinus
and trabeculae but also in vessel endothelial cells. Two recent
studies established a link between WNT-signaling, extracellular
matrix rigidity, barrier properties and invasion. Barbolina et
al.[45] showed that matrix mechanical properties might regulate
DKK1 expression in epithelial ovarian cancer cells in vitro and
that siRNA silencing of DKK1 expression significantly enhanced
invasion. Reis et al.[46] showed that Wnt-pathway inactivation in
glioma via Dkk1 resulted in a higher vascular density and
disrupted barrier function. They assumed that an active WNT
signaling might be necessary for normalized and quiescent tumor
vessels with increased barrier properties via PDGF-B expression
induction.
The potential involvement of DKK1 and the WNT-pathway is
further indicated by deregulation of associated genes (MSX1,
HOXA10, DKK1, MET and CCND1) and by prediction of a b-
catenin inactivation (Fig. 4a). MSX1 induces the WNT-pathway
antagonist gene DKK1.[47] DKK1 also exhibits binding sites for
HOXA10.[48] Because DKK1 can inhibit the WNT/b-catenin
pathway[49,50] whereas its own expression is induced by the b-
catenin/TCF complex[39], DKK1 imposes a negative force-
feedback loop on itself[51] and can suppress expression of b-
catenin target molecules such as CCND1. In breast cancer and
colon cancer cells it has been found that inhibition of b-catenin
might enhance invasive potential via upregulation of uPA/uPAR
at mRNA and protein level[52]. Increased DKK1 serum
concentrations have been observed in patients suffering from
ESC[37], and high expression levels have been shown to be a
Figure 5. Representative immunohistochemical staining images of the investigated lymph nodes. Lymph nodes were stained using a
polyclonal antibody against DKK1 (1:100, abcam, #ab61034) and counterstained with hematoxylin. a) Representative DKK1 negative lymph node.
Scale bar: 200 mm. b) Representative DKK1 positive lymph node. The subcapsular sinus is marked with (I) and the intermediary sinus and trabeculae
with (II). Scale bar: 200 mm. c) DKK1 positive vascular endothelial cells. Scale bar: 100 mm.
doi:10.1371/journal.pone.0102552.g005
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prognostic biomarker for esophageal carcinomas[53]. In a very
speculative outline tumor secreted DKK1 might potentially inhibit
the WNT pathway in the regional lymph nodes thus inactivating
b-catenin and down-regulating the lymph node native DKK1
gene. In this case the tumor secreted DKK1 would probably not
be observed in the immunohistochemical staining because it is
bound to the receptors and might not be accessible by the
antibody. That however would imply that the lymph node native
DKK1 does not inhibit the WNT pathway.
A number of existing publications underscore that DKK1 might
be a highly interesting diagnostic biomarker and therapeutic
target. On diagnostic level DKK1 is reported as good serologic
and prognostic biomarker for patients suffering from lung and
esophageal carcinoma [37], as well as for patients with cervical
cancer.[54] On therapeutic level a blockade of DKK1 using
neutralizing antibodies (BHQ880, Novartis) was reported in a
murine mouse model of multiple myeloma.[55] Furthermore
DKK1 has been suggested as therapeutic target in patients
suffering from breast cancer [56] or hepatocellular carcinoma
[57,58] and a patent claim [59] on ‘‘using antibodies and antibody
fragments capable of treating or preventing cancers associated with
the over-expression and/or up-regulation of DKK1‘‘ is public since
2009.
In conclusion and to the authors’ best knowledge, this is the first
study to analyze the hypothesis of a tumor-adjacent lymphatic
metastatic niche in esophageal carcinoma patients. Our findings
strongly support the work published by Hirakawa et al.[13] and
suggest that previous insights gained in mice also apply to patients.
The results lead us to assume that preparation of a lymph
metastatic niche takes place ahead of invasion and that this process
progresses over more than one step. After initial immune response
activation an advanced pre-invasive phenotype associated with
WNT signaling deregulation, especially DKK1, might mark the
lymph nodes’ state on the verge of invasion.
The fact that metastasis-free lymph nodes already show
alterations could change the view on the so-called local disease.
On the long term it might have direct clinical impact and
relevance for disease diagnosis and therapy selection. Our insights
in future might a) help improving classification by better defining
the intermediate stage between metastasis-free and invaded lymph
nodes and b) help better identify patients with an increased
metastatic risk that might need closer post-surgical observation or
treatment, and c) help find therapies, which could reduce the risk
of the ‘‘upcoming’’ metastatic invasion by restoring the lymph
nodes’ protective shield and finally d) raise awareness that targeted
treatment of the metastatic niche alongside targeting the tumor
cells might improve treatment outcome – a concept that
potentially might be called ‘‘Assistance to Self-assistance’’. The
current paradigm in cancer treatment is targeting the tumor or
metastatic cells. If a barrier is breached, however, or the
environmental conditions in the niche are fit for metastatic
invasion, then assisting classic targeted therapy by as well targeting
these alterations within the metastatic niche might increase
therapy effectiveness. Understanding the underlying mechanisms
might help find solutions for such a niche-targeted therapy.
Until then our results should be validated in a bigger study
setting and the precise role of DKK1 within lymph nodes remains
to be investigated.
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